MARKER THERAPEUTICS INC (MRKR) Forecast, Price Target & Analyst Ratings
NASDAQ:MRKR • US57055L2060
1.4 USD
+0.02 (+1.45%)
Last: Mar 9, 2026, 09:36 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MARKER THERAPEUTICS INC (MRKR).
Forecast Snapshot
Consensus Price Target
$9.21
+ 557.54% Upside
Next Earnings Forecast
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$0.20
Revenue Estimate695.64K
ChartMill Buy Consensus
82.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.21
Upside
+ 557.54%
From current price of $1.40 to mean target of $9.21, Based on 9 analyst forecasts
Low
$5.66
Median
$9.18
High
$13.13
Price Target Revisions
1 Month
0.00%
3 Months
10.51%
Price Target Summary
9 analysts have analysed MRKR and the average price target is 9.21 USD. This implies a price increase of 557.54% is expected in the next year compared to the current price of 1.4.
The average price target has been revised upward by 10.51% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
MRKR was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about MRKR.
In the previous month the buy percentage consensus was at a similar level.
MRKR was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-08 | HC Wainwright & Co. | Initiate | Buy |
| 2025-04-01 | WBB Securities | Reiterate | Strong Buy -> Strong Buy |
| 2025-03-05 | Canaccord Genuity | Initiate | Buy |
| 2024-10-21 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2024-04-30 | Ladenburg Thalmann | Initiate | Buy |
| 2022-02-17 | Roth Capital | Downgrade | Buy -> Neutral |
| 2021-03-25 | Piper Sandler | Initiate | Overweight |
| 2021-03-19 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-03-18 | Cantor Fitzgerald | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$0.20
Revenue Estimate695.64K
Revenue Q2Q-69.11%
EPS Q2Q52.24%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-5.67%
EPS (1 Month)
0.00%
EPS (3 Months)
-0.86%
Next Earnings Summary
MRKR is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -0.2 USD and the consensus revenue estimate is 695.64K USD.
The next earnings revenue estimate has been revised downward by 5.67% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 9.01M 626.61% | 3.311M -63.25% | 6.591M 99.06% | 3.162M -52.03% | 2.754M -12.90% | 19.875M 621.68% | 125.57M 531.80% | 164.86M 31.29% | 323.24M 96.07% | 341.07M 5.52% | 440.72M 29.22% | |
| EBITDA YoY % growth | -27.16M 27.22% | N/A | N/A | -14.679M -48.73% | -16.993M -15.76% | -16.313M 4.00% | 48.177M 395.33% | 30.452M -36.79% | 58.064M 90.67% | 241.7M 316.26% | 321.43M 32.99% | |
| EBIT YoY % growth | -29.95M 24.12% | -14.581M 51.31% | -11.118M 23.75% | -14.92M -34.19% | -24.758M -65.94% | -22.775M 8.01% | 42.091M 284.81% | 59.979M 42.50% | 152.06M 153.52% | 241.7M 58.95% | 321.43M 32.99% | |
| Operating Margin | -332.41% | -440.38% | -168.69% | -471.85% | -899.00% | -114.59% | 33.52% | 36.38% | 47.04% | 70.87% | 72.93% | |
| EPS YoY % growth | -3.58 32.45% | N/A 3.13% | -1.20 65.40% | -0.96 19.82% | -1.47 -52.65% | -0.97 33.80% | 1.05 208.04% | 0.62 -41.26% | 1.15 85.95% | 4.06 253.78% | 5.29 30.40% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 52.24% | -0.22 37.67% | -0.28 5.03% | -0.28 -129.50% | -0.21 -6.78% |
| Revenue Q2Q % growth | 695.64K -69.11% | 612K 75.36% | 612K -28.92% | 612K -50.36% | 612K -12.02% |
| EBITDA Q2Q % growth | -3.456M -40.06% | -4.182M | -5.202M -60.58% | -5.304M -63.73% | -5.508M -59.39% |
| EBIT Q2Q % growth | -3.698M 4.24% | -4.182M -0.64% | -5.202M -22.08% | -5.304M -148.23% | -5.508M -48.95% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
5.96%
EPS Next 5 Year
20.25%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
32.80%
Revenue Next 5 Year
81.00%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-239.79%
EBIT Next 5 Year
137.29%
MARKER THERAPEUTICS INC / MRKR Forecast FAQ
What is the price target for MRKR stock?
9 analysts have analysed MRKR and the average price target is 9.21 USD. This implies a price increase of 557.54% is expected in the next year compared to the current price of 1.4.
Can you provide the upcoming earnings date for MARKER THERAPEUTICS INC?
MARKER THERAPEUTICS INC (MRKR) will report earnings on 2026-03-30, after the market close.
What are the consensus estimates for MARKER THERAPEUTICS INC (MRKR) next earnings?
The consensus EPS estimate for the next earnings of MARKER THERAPEUTICS INC (MRKR) is -0.2 USD and the consensus revenue estimate is 695.64K USD.
Can you provide the consensus rating for MARKER THERAPEUTICS INC stock?
The consensus rating for MARKER THERAPEUTICS INC (MRKR) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.